Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients (Q42716087)

5 November 2017

title

Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients (English)

1 reference

non-small-cell lung carcinoma

5 November 2017

1 reference

1 reference

1 reference

Mengmeng Yang

1

1 reference

5 November 2017

Baoen Shan

2

1 reference

5 November 2017

Qiaoxia Li

3

1 reference

5 November 2017

Xiaoming Song

4

1 reference

5 November 2017

Jie Cai

5

1 reference

5 November 2017

Jianyun Deng

6

1 reference

5 November 2017

Likun Zhang

7

1 reference

5 November 2017

Zhenjian Du

8

1 reference

5 November 2017

Junjie Lu

9

1 reference

5 November 2017

Taiping Chen

10

1 reference

5 November 2017

Jean-Pierre Wery

11

1 reference

5 November 2017

Yiyou Chen

12

1 reference

5 November 2017

Qixiang Li

13

1 reference

5 November 2017

language of work or name

English

0 references

publication date

3 October 2012

1 reference

International Journal of Cancer

5 November 2017

published in

1 reference

5 November 2017

volume

132

1 reference

5 November 2017

issue

2

1 reference

5 November 2017

page(s)

E74-84

1 reference

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

5 November 2017

cites work

1 reference

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

EGFR and KRAS mutations in lung carcinoma: molecular testing by using cytology specimens.

21 January 2018

1 reference

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

21 January 2018

1 reference

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

21 January 2018

1 reference

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer

21 January 2018

1 reference

EGFR inhibition in non-small cell lung cancer: resistance, once again, rears its ugly head

21 January 2018

1 reference

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

Signaling networks assembled by oncogenic EGFR and c-Met

21 January 2018

1 reference

Genome remodelling in a basal-like breast cancer metastasis and xenograft

21 January 2018

1 reference

A new model of patient tumor-derived breast cancer xenografts for preclinical assays

21 January 2018

1 reference

Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.

21 January 2018

1 reference

Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts

21 January 2018

1 reference

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

21 January 2018

1 reference

Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts

21 January 2018

1 reference

New drugs in the treatment of gastric tumors

21 January 2018

1 reference

EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung

21 January 2018

1 reference

Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports

21 January 2018

1 reference

Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

21 January 2018

1 reference

Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.

21 January 2018

1 reference

Detection of mutations in EGFR in circulating lung-cancer cells

21 January 2018

1 reference

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.27813

1 reference

5 November 2017

1 reference